Skip to main content
. Author manuscript; available in PMC: 2009 Jul 30.
Published in final edited form as: Alzheimer Dis Assoc Disord. 2008;22(3):209–221. doi: 10.1097/WAD.0b013e31816653bc

Fig 1.

Fig 1

Raw data for BDS versus Duration of Illness (symptoms) for A) NO-RX group (no medications), B) CI group, and C) COMBO group of subjects. Thin lines connect data for an individual (subject), while the thick line is the best fitting ordinary least square (OLS) regression line for the data. There is progressive shallowing of the slope for the OLS regression lines going from NO-RX to CI to COMBO that is consistent with a respective slower rate of cognitive decline with use of medication(s).